CereVasc, a Massachusetts-based developer of the eShunt System for treating communicating hydrocephalus, has raised $85 million in Series C funding led by Piper Sandler Merchant Banking. The eShunt System is a novel endovascularly implantable CSF shunt deployed via a percutaneous femoral venous approach under X-ray guidance in a minimally invasive procedure lasting about one hour. The capital will advance the STRIDE pivotal trial, support PMA submission, and prepare for U.S. commercialization.
Endovascular Approach Challenges Traditional Shunts
The timing comes amid growing interest in minimally invasive alternatives for hydrocephalus. Traditional ventriculoperitoneal shunts require open brain surgery and carry failure rates exceeding 40 percent within two years. CereVasc positions eShunt as the first endovascular, transvenous option that avoids craniotomy, general anesthesia, and many associated complications.
High Failure Rates of Conventional VP Shunts
Communicating hydrocephalus affects more than 320,000 patients in the United States, including those with normal pressure hydrocephalus. Current solutions involve invasive neurosurgical procedures with high rates of infection, obstruction, and revision surgeries. Patients often face extended recovery and repeated interventions.
eShunt Delivers Minimally Invasive CSF Diversion
The eShunt System uses catheter-based placement through a small leg incision to drain fluid into a nearby vein. This contrasts with established competitors such as Medtronic and Integra LifeSciences, which rely on open surgical implantation of ventriculoperitoneal shunts. The approach targets communicating hydrocephalus cases, including normal pressure hydrocephalus in older adults.
As CEO Dan Levangie noted:
“This Series C financing is a meaningful milestone for CereVasc… accelerating our path toward a minimally invasive surgery.”
Strategic Investors Signal Commercial Path
Piper Sandler Merchant Banking led the oversubscribed round, with participation from new investors Johnson & Johnson Innovation – JJDC and Medtronic alongside existing backers Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds. The involvement of two major medtech corporations alongside growth equity firms validates the technology's alignment with neurological device priorities and suggests potential future strategic pathways.
Hydrocephalus Shunts Market Expands Steadily
The hydrocephalus shunts market stands at $910.6 million in 2026 and is projected to reach $1.495 billion by 2033. Key drivers include an aging population increasing normal pressure hydrocephalus cases and demand for reduced surgical trauma. CereVasc's positioning as the only endovascular shunt gives it first-mover potential in a segment still dominated by conventional open-surgery devices.
Manufacturing Expansion and 2028 Target
The company is opening a 15,000 square foot facility in Wilmington, Massachusetts, to support scale-up. It targets regulatory approval in 2028 following completion of the STRIDE pivotal trial and PMA submission. The round also adds board expertise to guide commercialization.